Monitored Implementation of COVID-19 Rapid Antigen Screening at Taxi Ranks in Johannesburg, South Africa.
COVID-19
SARS-CoV-2
South Africa
antigen
community-based testing
differentiated care
digital
rapid
taxi rank
testing
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
03 Feb 2022
03 Feb 2022
Historique:
received:
30
12
2021
revised:
23
01
2022
accepted:
28
01
2022
entrez:
25
2
2022
pubmed:
26
2
2022
medline:
26
2
2022
Statut:
epublish
Résumé
Digital tools can support community-based decentralized testing initiatives to broaden access to COVID-19 diagnosis, especially in high-transmission settings. This operational study investigated the use of antigen-detecting rapid diagnostic tests (Ag-RDTs) for COVID-19 combined with an end-to-end digital health solution, in three taxi ranks in Johannesburg, South Africa. Members of the public were eligible if they were aged ≥18 years, could read, and had a cellphone. Over 15,000 participants, enrolled between June and September 2021, were screened for COVID-19 risk factors. A digital risk questionnaire identified 2061 (13%) participants as moderate risk and 2987 (19%) as high risk, based on symptoms and/or recent exposure to a known case. Of this group referred for testing, 3997 (79%) received Ag-RDTs, with positivity rates of 5.1% in the "high-risk" group and 0.8% in the "moderate-risk" group. A subset of 569 randomly selected participants received additional PCR testing. Sensitivity of the Ag-RDT in this setting was 40% (95% CI: 30.3%, 50.3%); most false negatives had high cycle threshold values (>25), hence low viral loads. Over 80% of participants who tested positive completed a 2-week phone-based follow-up questionnaire. Overall, the digital tool combined with Ag-RDTs enhanced community-based decentralized COVID-19 testing service delivery, reporting and follow-up.
Identifiants
pubmed: 35204493
pii: diagnostics12020402
doi: 10.3390/diagnostics12020402
pmc: PMC8871379
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : FIND and Ezintsha
ID : NL-COVI01
Références
Cochrane Database Syst Rev. 2021 Mar 24;3:CD013705
pubmed: 33760236
PLoS Med. 2021 Nov 24;18(11):e1003867
pubmed: 34818336
PLoS Med. 2021 Aug 12;18(8):e1003735
pubmed: 34383750
Lancet Microbe. 2021 Jan;2(1):e13-e22
pubmed: 33521734
Lancet Glob Health. 2021 Sep;9(9):e1216-e1225
pubmed: 34252381
JMIR Mhealth Uhealth. 2020 Apr 21;8(4):e17246
pubmed: 32314977
J Clin Tuberc Other Mycobact Dis. 2019 Jun 19;16:100110
pubmed: 31720434
Front Pediatr. 2021 Mar 16;9:645577
pubmed: 33796490
JMIR Mhealth Uhealth. 2020 Jan 15;8(1):e13133
pubmed: 31939743
Epidemiol Infect. 2020 Sep 11;148:e208
pubmed: 32912370
EClinicalMedicine. 2021 Jun;36:100924
pubmed: 34101770
Malar J. 2019 Feb 21;18(1):45
pubmed: 30791909
Nat Med. 2020 Aug;26(8):1183-1192
pubmed: 32770165
PLoS One. 2021 Jul 16;16(7):e0253927
pubmed: 34270582
MMWR Morb Mortal Wkly Rep. 2021 Jan 01;69(5152):1642-1647
pubmed: 33382679
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):1809-1814
pubmed: 32956925
EClinicalMedicine. 2021 Jan;31:100677
pubmed: 33521610
Lancet Infect Dis. 2021 Oct;21(10):1365-1372
pubmed: 34051886
Reprod Health. 2020 Jul 31;17(1):116
pubmed: 32736561
Am J Epidemiol. 2013 Mar 15;177(6):556-61
pubmed: 23423215